Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLR1A | O95602 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 5/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202091 | 1.00 | MALT1 (0.40) | MALT1KMT2APOLR1AJAK1CCR3 | |
| SCHEMBL2199901 | 0.91 | MALT1 (0.49) | MALT1KMT2ACCR3 | |
| SCHEMBL2199905 | 0.91 | MALT1 (0.49) | MALT1KMT2ACCR3 | |
| SCHEMBL2198942 | 0.87 | KMT2A (0.44) | MALT1KMT2ACCR3 | |
| SCHEMBL2198937 | 0.87 | KMT2A (0.44) | MALT1KMT2ACCR3 | |
| SCHEMBL2198795 | 0.86 | KMT2A (0.39) | KMT2APOLR1AJAK1GPR119KDM1A | |
| SCHEMBL2198792 | 0.86 | KMT2A (0.39) | KMT2APOLR1AJAK1GPR119KDM1A | |
| SCHEMBL2200679 | 0.86 | MALT1 (0.40) | MALT1KMT2ACCR3ALDH1A1 | |
| SCHEMBL2200677 | 0.86 | MALT1 (0.40) | MALT1KMT2ACCR3ALDH1A1 | |
| SCHEMBL2201732 | 0.86 | MALT1 (0.40) | MALT1KMT2ACCR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | MALT1 3122/4885KMT2A 4057/4885POLR1A 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.